VOGX (Vogenx) OCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VOGX Vogenx Inc VOGX
8 GF Score
Price $14.09
View Full Analysis

What is Vogenx OCF Margin %?

Vogenx VOGX +8.38% 8 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates VOGX with a GF Score™ of 8/100. Among 955 Biotechnology companies, Vogenx ranks worse than 104711.94% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Vogenx's Cash Flow from Operations for the six months ended in Dec. 2025 was $-1.11 Mil. Vogenx's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Vogenx's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Vogenx's current OCF Yield % is -0.57%.

The historical rank and industry rank for Vogenx's OCF Margin % or its related term are showing as below:


VOGX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.98
* Ranked among companies with meaningful OCF Margin % only.

Vogenx OCF Margin % Related Terms

Vogenx OCF Margin % Historical Data

* Premium members only.

The historical data trend for Vogenx's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vogenx OCF Margin % Chart

Vogenx Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 0.00

Vogenx Semi-Annual Data
Dec24 Dec25
OCF Margin % 0.00 0.00
VOGX
8GF Score
Vogenx Inc VOGX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vogenx OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Vogenx's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.112/0
= %

Vogenx's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.112/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Vogenx (VOGX) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vogenx and its competitors. According to the industry distribution chart, Vogenx ranks #999999 out of 955 companies in the Biotechnology industry.
Is Vogenx's OCF Margin % too high?
Vogenx's current OCF Margin % is 0.00%. Based on the distribution chart, Vogenx ranks #999999 out of 955 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vogenx has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vogenx's OCF Margin % compare to ?
According to the Biotechnology industry distribution chart, Vogenx ranks #999999 out of 955 companies for OCF Margin %. This places Vogenx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vogenx and its competitors. Vogenx's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vogenx stock overvalued right now?
Vogenx (VOGX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Vogenx's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Vogenx (VOGX), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vogenx Business Description

Comparable Companies
Address 3901 Barrett Drive, P.O. Box 19469, Suite 300, Raleigh, NC, USA, 27609
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
8GF Score

Get the complete analysis for VOGX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.09
Price